SCHEMBL29324793

SCHEMBL29324793

CC(C)OCCSc1cccc(C(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
TSHR P16473 1/20 0.38
HDAC4 P56524 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
KIF11 P52732 1/20 0.36
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MDM4 O15151 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
TYR P14679 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
CA5A P35218 1/20 0.35
HTT P42858 1/20 0.35
MDM2 Q00987 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26575423 0.81 MAOA (0.46) KDM4ETSHRHDAC4HDAC8KIF11
SCHEMBL12417828 0.79 MAOA (0.50) KDM4ETSHRHDAC4HDAC8KIF11
SCHEMBL25144619 0.79 MEN1 (0.46) KDM4EALDH1A1SMN1; SMN2TYRHPGD
SCHEMBL25144725 0.78 MAOA (0.36) MAOAMAOB
SCHEMBL12461692 0.77 PTGS2 (0.49) KDM4ETSHRHDAC4HDAC8KIF11
SCHEMBL20624731 0.75 KIF11 (0.43) KDM4ETSHRHDAC4HDAC8KIF11
SCHEMBL11263969 0.75 MAOA (0.42) KDM4ETSHRHDAC4HDAC8KIF11
SCHEMBL12394796 0.75 MAOA (0.46) KDM4ETSHRHDAC4HDAC8KIF11
SCHEMBL15617290 0.75 HDAC4 (0.39) KDM4ETSHRHDAC4HDAC8KIF11
SCHEMBL20738232 0.71 ATM (0.39) KDM4ETSHRHDAC4HDAC8KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R KDM4E 3972/4885TSHR 560/4885HDAC4 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.